FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2778164077> ?p ?o ?g. }

• W2778164077 endingPage "306" @default.
• W2778164077 startingPage "299" @default.
• W2778164077 abstract "New insights in thyroid cancer biology propelled the development of targeted therapies as salvage treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC), and the tyrosine kinase inhibitor (TKI) lenvatinib has recently become available as a new line of therapy for RR-DTC. The aim of this study is to investigate clinical factors related to the efficacy of TKI therapy in recurrent RR-DTC patients and identify the optimal timing for the start of TKI therapy. The subjects consisted of 29 patients with progressive RR-DTC, 9 males and 20 females, median age 66 years. A univariate analysis was conducted in relation to progression free survival (PFS) and overall survival (OS) by the Kaplan-Meier method for the following variables: age, sex, histology of the primary tumor, thyroglobulin doubling time before the start of lenvatinib therapy, site of the target lesions, presence of a tumor-mediated symptom at the start of lenvatinib therapy, and baseline tumor size of the target lesions. Median duration of lenvatinib therapy was 14.7 months and median drug intensity was 9.5 mg. At the time of the data cut-off for the analysis, 9 patients (31.0%) have died of their disease (DOD), and a PR (partial response), SD (stable disease), and PD (progressive disease) were observed in 20 patients (69%), 6 patients (20.7%), 3 patients (10.3%), respectively. Univariate analyses showed that the presence of a symptom was the only factor significantly related to poorer PFS and OS. Clinical benefit of TKI therapy will be possibly limited when the therapy starts after tumor-mediated symptoms appear." @default.
• W2778164077 created "2018-01-05" @default.
• W2778164077 creator A5014372193 @default.
• W2778164077 creator A5014603629 @default.
• W2778164077 creator A5020776903 @default.
• W2778164077 creator A5025607253 @default.
• W2778164077 creator A5028206707 @default.
• W2778164077 creator A5037955901 @default.
• W2778164077 creator A5039360739 @default.
• W2778164077 creator A5044601192 @default.
• W2778164077 creator A5048927060 @default.
• W2778164077 creator A5049987852 @default.
• W2778164077 creator A5053804133 @default.
• W2778164077 creator A5070970285 @default.
• W2778164077 creator A5082059498 @default.
• W2778164077 date "2018-01-01" @default.
• W2778164077 modified "2023-10-06" @default.
• W2778164077 title "Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients" @default.
• W2778164077 cites W1936739249 @default.
• W2778164077 cites W1967792499 @default.
• W2778164077 cites W1984185945 @default.
• W2778164077 cites W1991866477 @default.
• W2778164077 cites W2033054128 @default.
• W2778164077 cites W2069792474 @default.
• W2778164077 cites W2072114559 @default.
• W2778164077 cites W2079595221 @default.
• W2778164077 cites W2106695112 @default.
• W2778164077 cites W2112129582 @default.
• W2778164077 cites W2118988113 @default.
• W2778164077 cites W2133354058 @default.
• W2778164077 cites W2139663958 @default.
• W2778164077 cites W2145150141 @default.
• W2778164077 cites W2168076926 @default.
• W2778164077 cites W2402807966 @default.
• W2778164077 cites W2508537271 @default.
• W2778164077 doi "https://doi.org/10.1507/endocrj.ej17-0365" @default.
• W2778164077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29269689" @default.
• W2778164077 hasPublicationYear "2018" @default.
• W2778164077 type Work @default.
• W2778164077 sameAs 2778164077 @default.
• W2778164077 citedByCount "27" @default.
• W2778164077 countsByYear W27781640772018 @default.
• W2778164077 countsByYear W27781640772019 @default.
• W2778164077 countsByYear W27781640772020 @default.
• W2778164077 countsByYear W27781640772021 @default.
• W2778164077 countsByYear W27781640772022 @default.
• W2778164077 countsByYear W27781640772023 @default.
• W2778164077 crossrefType "journal-article" @default.
• W2778164077 hasAuthorship W2778164077A5014372193 @default.
• W2778164077 hasAuthorship W2778164077A5014603629 @default.
• W2778164077 hasAuthorship W2778164077A5020776903 @default.
• W2778164077 hasAuthorship W2778164077A5025607253 @default.
• W2778164077 hasAuthorship W2778164077A5028206707 @default.
• W2778164077 hasAuthorship W2778164077A5037955901 @default.
• W2778164077 hasAuthorship W2778164077A5039360739 @default.
• W2778164077 hasAuthorship W2778164077A5044601192 @default.
• W2778164077 hasAuthorship W2778164077A5048927060 @default.
• W2778164077 hasAuthorship W2778164077A5049987852 @default.
• W2778164077 hasAuthorship W2778164077A5053804133 @default.
• W2778164077 hasAuthorship W2778164077A5070970285 @default.
• W2778164077 hasAuthorship W2778164077A5082059498 @default.
• W2778164077 hasBestOaLocation W27781640771 @default.
• W2778164077 hasConcept C121332964 @default.
• W2778164077 hasConcept C121608353 @default.
• W2778164077 hasConcept C126322002 @default.
• W2778164077 hasConcept C142424586 @default.
• W2778164077 hasConcept C143998085 @default.
• W2778164077 hasConcept C144301174 @default.
• W2778164077 hasConcept C2776264508 @default.
• W2778164077 hasConcept C2776694085 @default.
• W2778164077 hasConcept C2778820342 @default.
• W2778164077 hasConcept C2778835679 @default.
• W2778164077 hasConcept C2779761222 @default.
• W2778164077 hasConcept C2780775027 @default.
• W2778164077 hasConcept C2781230642 @default.
• W2778164077 hasConcept C38180746 @default.
• W2778164077 hasConcept C526584372 @default.
• W2778164077 hasConcept C71924100 @default.
• W2778164077 hasConcept C87355193 @default.
• W2778164077 hasConceptScore W2778164077C121332964 @default.
• W2778164077 hasConceptScore W2778164077C121608353 @default.
• W2778164077 hasConceptScore W2778164077C126322002 @default.
• W2778164077 hasConceptScore W2778164077C142424586 @default.
• W2778164077 hasConceptScore W2778164077C143998085 @default.
• W2778164077 hasConceptScore W2778164077C144301174 @default.
• W2778164077 hasConceptScore W2778164077C2776264508 @default.
• W2778164077 hasConceptScore W2778164077C2776694085 @default.
• W2778164077 hasConceptScore W2778164077C2778820342 @default.
• W2778164077 hasConceptScore W2778164077C2778835679 @default.
• W2778164077 hasConceptScore W2778164077C2779761222 @default.
• W2778164077 hasConceptScore W2778164077C2780775027 @default.
• W2778164077 hasConceptScore W2778164077C2781230642 @default.
• W2778164077 hasConceptScore W2778164077C38180746 @default.
• W2778164077 hasConceptScore W2778164077C526584372 @default.
• W2778164077 hasConceptScore W2778164077C71924100 @default.
• W2778164077 hasConceptScore W2778164077C87355193 @default.
• W2778164077 hasIssue "3" @default.
• W2778164077 hasLocation W27781640771 @default.

• next